Activin

Overview

Activins are dimeric proteins belonging to the TGF-beta superfamily, formed by pairing of inhibin beta subunits. They were originally identified in the 1980s as gonadal factors that stimulate follicle-stimulating hormone (FSH) release from the anterior pituitary — functionally opposing inhibin, which suppresses FSH. The name "activin" reflects this stimulatory action on the pituitary gonadotroph.

Three major forms exist based on subunit composition: activin A (beta-A/beta-A homodimer), activin B (beta-B/beta-B homodimer), and activin AB (beta-A/beta-B heterodimer). Activin A is the most abundant and best-characterized form. These subunits are the same beta subunits found in inhibin, but in inhibin they are paired with an alpha subunit instead of forming beta-beta dimers.

Beyond their role in reproductive endocrinology, activins have emerged as far-reaching signaling molecules involved in embryonic development, wound healing, inflammation, erythropoiesis, bone metabolism, and muscle regulation. Activin shares the ActRIIB receptor with myostatin, meaning activin signaling contributes to the same muscle-regulatory pathway — a fact that has complicated anti-myostatin drug development.

Structure

Activins are disulfide-linked dimers of inhibin beta subunits:

• Activin A: beta-A/beta-A homodimer (~26 kDa)
• Activin B: beta-B/beta-B homodimer (~26 kDa)
• Activin AB: beta-A/beta-B heterodimer (~26 kDa)
• Subunit genes: INHBA (beta-A, chromosome 7p14.1), INHBB (beta-B, chromosome 2q14.2)
• Receptors: Activin type IIA and type IIB receptors (ActRIIA, ActRIIB), with ALK4 as the type I receptor

Structural features:

• Cystine knot motif — characteristic of TGF-beta superfamily; six conserved cysteines form three intramolecular disulfide bonds
• Interchain disulfide bond — links the two beta subunits into the active dimer
• Produced as precursor proteins — cleaved by proprotein convertases to release the mature C-terminal domain

Mechanism of Action

Receptor Signaling

Activins signal through the canonical Smad pathway:

1. Activin binds ActRIIA or ActRIIB (type II activin receptors) with high affinity
2. The type II receptor recruits and phosphorylates the type I receptor ALK4 (or ALK7 for activin B)
3. Activated ALK4 phosphorylates Smad2 and Smad3
4. Phospho-Smad2/3 complex with the common mediator Smad4
5. The Smad complex translocates to the nucleus and activates or represses target gene transcription

This pathway is shared with myostatin, which also signals through ActRIIB/ALK4/Smad2/3. Follistatin and inhibin are the primary endogenous antagonists of activin signaling.

FSH Regulation

Activin's classical role is stimulating FSH synthesis and secretion:

• Acts directly on anterior pituitary gonadotroph cells
• Upregulates FSHbeta gene expression through Smad-dependent transcription
• Works in concert with GnRH pulsatile signaling
• Opposed by inhibin (which suppresses FSH) and follistatin (which sequesters activin)
• This activin-inhibin axis provides fine-tuned negative feedback regulation of the reproductive axis

Muscle and Metabolic Effects

• Activin A signals through the same ActRIIB/Smad2/3 pathway as myostatin
• Elevated activin A promotes muscle atrophy and contributes to cachexia in cancer
• ActRIIB-Fc decoy receptors (e.g., ACE-031) block both myostatin and activin, producing more robust muscle hypertrophy than myostatin-only blockade — but also more side effects
• This receptor overlap explains why selective anti-myostatin antibodies show less muscle effect than ActRIIB traps in clinical trials

Erythropoiesis

• Activin A promotes erythroid differentiation
• ActRIIA ligand traps (luspatercept/Reblozyl) block activin signaling to treat ineffective erythropoiesis
• Luspatercept is FDA-approved for anemia in myelodysplastic syndromes and beta-thalassemia

Research Summary

Pharmacokinetics

• Half-life: Approximately 10-20 minutes for free activin in circulation; significantly extended when bound to follistatin or FLRG
• Circulating levels: Activin A: 200-400 pg/mL (varies by age, sex, reproductive status); increases with age and in inflammatory states
• Regulation: Locally produced in many tissues; circulating levels reflect gonadal and extra-gonadal sources
• Binding proteins: Follistatin and FLRG (follistatin-related gene) bind and neutralize circulating activin

Clinical Relevance: Luspatercept

Luspatercept (Reblozyl) is an ActRIIA-Fc fusion protein that traps activin and related TGF-beta ligands:

• Approved indications: Anemia in lower-risk MDS with ring sideroblasts; anemia in beta-thalassemia requiring regular transfusions
• Mechanism: By blocking activin signaling, promotes late-stage erythroid maturation that is otherwise inhibited
• Relevance to activin biology: Validates the concept that excess activin signaling causes pathology and that targeted blockade has therapeutic value

Common Discussion Topics

1. Activin vs. myostatin in muscle wasting — Both signal through ActRIIB, but activin A may be the more important driver of muscle wasting in cancer cachexia. This has shifted some drug development attention from myostatin-only to combined activin/myostatin blockade.

2. The activin-inhibin-follistatin triad — These three proteins form an interlocking regulatory system. Activin stimulates, inhibin opposes, and follistatin sequesters. Understanding this triad is essential for interpreting reproductive endocrinology and TGF-beta signaling.

3. Activin as an aging biomarker — Circulating activin A levels increase with age and correlate with frailty, muscle wasting, and anemia. Some researchers have proposed activin as a biomarker of biological aging.

4. Fibrosis involvement — Activin A promotes fibrotic remodeling in multiple organs, making it a potential therapeutic target in conditions such as pulmonary fibrosis, liver fibrosis, and cardiac fibrosis.

5. Dual-signaling complexity — Because activin and myostatin share receptors, therapeutic agents targeting ActRIIB affect both pathways. This creates both opportunities (broader efficacy) and challenges (broader side effects).

Related Compounds

• Inhibin — shares beta subunits with activin but suppresses FSH (opposing function)
• Follistatin — natural activin-binding protein that neutralizes activin signaling
• Myostatin — TGF-beta family member sharing the ActRIIB/Smad2/3 pathway
• GnRH — hypothalamic hormone that works with activin to regulate FSH secretion
• Relaxin — reproductive peptide with complementary roles in fertility